LENZ Therapeutics, Inc. (LENZ)
NASDAQ: LENZ · Real-Time Price · USD
32.63
+2.35 (7.76%)
Dec 20, 2024, 4:00 PM EST - Market closed
LENZ Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 15 | - |
| Gross Profit | - | - | 15 | - |
| Selling, General & Admin | 24.91 | 12.93 | 4.36 | 2.47 |
| Research & Development | 43.47 | 59.5 | 21.13 | 4.22 |
| Operating Expenses | 68.37 | 72.43 | 25.48 | 6.69 |
| Operating Income | -68.37 | -72.43 | -10.48 | -6.69 |
| Interest & Investment Income | 6.84 | 2.19 | 0 | - |
| Other Non Operating Income (Expenses) | 0.55 | 0.09 | 0.02 | -0.87 |
| Pretax Income | -60.99 | -70.15 | -10.46 | -7.56 |
| Income Tax Expense | -0.18 | -0.18 | 0.35 | - |
| Net Income | -60.81 | -69.97 | -10.81 | -7.56 |
| Net Income to Common | -60.81 | -69.97 | -10.81 | -7.56 |
| Shares Outstanding (Basic) | 23 | 10 | 9 | 9 |
| Shares Outstanding (Diluted) | 23 | 10 | 9 | 9 |
| Shares Change (YoY) | 486.94% | 2.47% | 1.05% | - |
| EPS (Basic) | -2.69 | -7.22 | -1.14 | -0.81 |
| EPS (Diluted) | -2.69 | -7.22 | -1.14 | -0.81 |
| Free Cash Flow | -71.6 | -60.41 | -4.13 | -5.4 |
| Free Cash Flow Per Share | -3.17 | -6.23 | -0.44 | -0.58 |
| Gross Margin | - | - | 100.00% | - |
| Operating Margin | - | - | -69.89% | - |
| Profit Margin | - | - | -72.07% | - |
| Free Cash Flow Margin | - | - | -27.52% | - |
| EBITDA | -68.34 | -72.41 | -10.48 | -6.69 |
| EBITDA Margin | - | - | -69.83% | - |
| D&A For EBITDA | 0.04 | 0.02 | 0.01 | 0 |
| EBIT | -68.37 | -72.43 | -10.48 | -6.69 |
| EBIT Margin | - | - | -69.89% | - |
| Revenue as Reported | - | - | 15 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.